APP
ICPT

Avantax Planning Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Avantax Planning Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-9
Closed -$1K – 1590
2018
Q1 		$1K Buy
+9
New +$542 ﹤0.01% 1783

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Avantax Planning Partners's ICPT Position: Q2 2018 in Review

Avantax Planning Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2018, closing a stake of 9 shares — an estimated $1K sold.

Avantax Planning Partners first reported a position in ICPT in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 163 funds tracked by Wall St. Rank hold ICPT as of Q2 2018.

  • Avantax Planning Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 9 Intercept Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1K.
  • Avantax Planning Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Intercept Pharmaceuticals, Inc. position peaked at $1K in Q1 2018.
  • 163 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.